Zenas Biopharma Inc

Insider buying surge at Zenas Biopharma shows modest confidence amid a 21 % weekly rally; incremental purchases hint at potential upside tied to upcoming clinical milestones.

Insider buying surge at Zenas Biopharma signals growing confidence in its immunology pipeline and potential upside, while highlighting the importance of clinical milestones and regulatory developments.

CEO Leon Moulder’s 100k‑share buying spree shows insider confidence in Zenas Biopharma’s immunology pipeline, hinting at a rebound amid volatile stock swings.